Search

• GSK and Enigma Diagnostics announce commercial partnership to develop point-of-care influenza diagnostics

  Media

  GSK & Enigma have signed agreements to develop and supply influenza tests to identify virus strains using its real-time PCR technology.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-enigma-diagnostics-announce-commercial-partnership-to-develop-point-of-care-influenza-diagnostics/

  First published: 20 July 2009

• GlaxoSmithKline update: A (H1N1) influenza vaccine development

  Media

  GSK has received orders from several governments aiming to stockpile a H1N1 adjuvanted influenza vaccine as a precautionary measure.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-a-h1n1-influenza-vaccine-development/

  First published: 14 May 2009

• GlaxoSmithKline update: influenza A (H1N1)

  Media

  GSK committed to supporting governments and health authorities around the world to respond to the emergence of the new H1N1 strain.

  https://www.gsk.com/en-gb/media/press-releases/glaxosmithkline-update-influenza-a-h1n1/

  First published: 30 April 2009

• Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection

  Media

  ViiV announced the FDA has approved Juluca®, complete regimen for the maintenance treatment of HIV-1 infection in virologically suppressed..

  https://www.gsk.com/en-gb/media/press-releases/juluca-approved-in-us-as-first-2-drug-regimen-once-daily-single-pill/

  First published: 21 November 2017

• Vir Biotechnology and GSK announce start of NIH-sponsored ACTIV-3 trial evaluating VIR-7831 in hospitalised adults with COVID-19

  Media

  Global Phase 3 trial will investigate the safety and efficacy of VIR-7831 in hospitalised adults with COVID-19

  https://www.gsk.com/en-gb/media/press-releases/vir-biotechnology-and-gsk-announce-start-of-nih-sponsored-activ-3-trial-evaluating-vir-7831-in-hospitalised-adults-with-covid-19/

  First published: 17 December 2020

• ViiV Healthcare Announces CHMP positive opinion to lower the age and weight limit for Tivicay® (dolutegravir) in children and adolescents living with HIV in Europe

  Media

  The CHMP has adopted a positive opinion to reduce the weight and age limit for the treatment of HIV with Tivicay.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-chmp-positive-opinion-to-lower-the-age-and-weight-limit-for-tivicay-dolutegravir-in-children-and-adolescents-living-with-hiv-in-europe/

  First published: 16 December 2016

• ViiV Healthcare announces FDA approval to lower the weight limit for dolutegravir in children and adolescents living with HIV

  Media

  The US Food and Drug Administration has approved a supplemental New Drug Application (sNDA) for dolutegravir 10mg and 25mg oral tablets.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-fda-approval-to-lower-the-weight-limit-for-dolutegravir-in-children-and-adolescents-living-with-hiv/

  First published: 10 June 2016

• Phase II study results showed comparable viral suppression rates at 96 weeks for a two-drug regimen of long-acting cabotegravir and rilpivirine and a three-drug regimen in patients with HIV

  Media

  LATTE-2 study results published in The Lancet and presented at International AIDS Society Meeting

  https://www.gsk.com/en-gb/media/press-releases/phase-ii-study-results-showed-comparable-viral-suppression-rates-at-96-weeks/

  First published: 24 July 2017

• ViiV Healthcare announces positive new dolutegravir data for the treatment of people living with HIV co-infected with tuberculosis

  Media

  INSPIRING study results contribute to extensive body of evidence for dolutegravir

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-positive-new-dolutegravir-data-for-the-treatment-of-people-living-with-hiv-co-infected-with-tuberculosis/

  First published: 05 March 2018

• ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

  Media

  SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca for treatment of virologically suppressed adults with HIV

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-announces-juluca-dolutegravirrilpivirine-maintains-hiv-viral-suppression-at-148-weeks/

  First published: 03 April 2019